Sacubitril/Valsartan

Generic Name: Sacubitril/Valsartan

Brand Names: -

Drug Type: -

Chemical Formula: -

CAS Number: -

Unique Ingredient Identifier: -

Indication: ⑴用于在有慢性心力衰竭(NYHA类别II-IV)患者中减低对心力衰竭的心血管死亡及住院治疗慢性心力衰竭和射血分数降低。本品通常与其他心力衰竭治疗结合，代替一种ACE抑制药或其他血管紧张素II受体阻断药。

⑵用于治疗原发性高血压.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Open-label Extension Study for CLCZ696G2301 (PARADISE-MI)

Phase 3

Withdrawn

Conditions: Post Myocardial Infarction

Interventions: Drug: sacubitril/valsartan

First Posted Date: 2020-11-19

Last Posted Date: 2021-11-26

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT04637555

Early Treatment of ARNI on Myocardial Remodeling and Progress

Phase 4

Conditions: Myocardial Infarction

Interventions: Drug: sacubitril/valsartan
Drug: perindopril
Other: Cardiopulmonary Exercise Test
Other: Echocardiogram

First Posted Date: 2020-04-13

Last Posted Date: 2020-04-14

Lead Sponsor: RenJi Hospital

Target Recruit Count: 280

Registration Number: NCT04342351

Locations: 🇨🇳
RenJi Hospital, Shanghai JiaoTong University, School of Medicine, Shanghai, Shanghai, China

Comparison of BNP and NT-proBNP in the Management of Patients With Chronic and Acute Heart Failure

Not Applicable

Conditions: Heart Failure

Interventions: Drug: Sacubitril/Valsartan

First Posted Date: 2019-09-27

Last Posted Date: 2019-09-27

Lead Sponsor: Unity Health Toronto

Target Recruit Count: 300

Registration Number: NCT04107220

Locations: 🇨🇦
St. Michael's Hospital, Toronto, Ontario, Canada

Efficacy and Safety of Sacubitril/Valsartan Compared With Enalapril on Morbidity, Mortality, and NT-proBNP Change in Patients With CCC

Phase 4

Active, not recruiting

Conditions: Heart Failure
Chagas Disease

Interventions: Drug: Enalapril
Drug: Sacubitril/valsartan

First Posted Date: 2019-07-17

Last Posted Date: 2024-12-27

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 919

Registration Number: NCT04023227

Locations: 🇲🇽
Novartis Investigative Site, Xalapa, Mexico

Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF)

Phase 3

Completed

Conditions: Heart Failure With Preserved Ejection Fraction (HFpEF)

Interventions: Drug: valsartan
Drug: sacubitril/valsartan
Drug: valsartan matching placebo
Drug: sacubitril/valsartan matching placebo

First Posted Date: 2019-06-17

Last Posted Date: 2024-07-29

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 467

Registration Number: NCT03988634

Locations: 🇺🇸
Boston Univeristy Medical Center ., Boston, Massachusetts, United States
🇺🇸
Colorado Heart and Vascular ., Lakewood, Colorado, United States
🇺🇸
Swedish Medical Ctr Cardiovascular Re, Seattle, Washington, United States

and more 83 locations

Sacubitril/Valsartan vs Lifestyle in Hypertrophic Cardiomyopathy

Phase 2

Completed

Conditions: Hypertrophic Cardiomyopathy

Interventions: Behavioral: Lifestyle
Drug: Sacubitril/Valsartan

First Posted Date: 2019-02-06

Last Posted Date: 2022-11-28

Lead Sponsor: Newcastle University

Target Recruit Count: 168

Registration Number: NCT03832660

Locations: 🇷🇸
Institute of Cardiovascular Diseases of Vojvodina, Sremska Kamenica, Serbia
🇮🇹
Azienda Ospedaliero Universitaria Careggi Florence, Florence, Italy
🇩🇪
University Hospital Regensburg, Regensburg, Germany

and more 2 locations

Open-label Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF

Phase 3

Completed

Conditions: Heart Failure

Interventions: Drug: sacubitril/valsartan

First Posted Date: 2018-12-24

Last Posted Date: 2024-07-16

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 216

Registration Number: NCT03785405

Locations: 🇹🇷
Novartis Investigative Site, Konak-Izmir, Turkey
🇺🇸
Mayo Clinic - Rochester, Rochester, Minnesota, United States

Prevention of Cardiac Dysfunction During Breast Cancer Therapy

Phase 2

Active, not recruiting

Conditions: Breast Cancer Female
Heart Failure

Interventions: Drug: Sacubitril/valsartan

First Posted Date: 2018-11-30

Last Posted Date: 2023-03-17

Lead Sponsor: Torbjorn Omland

Target Recruit Count: 214

Registration Number: NCT03760588

Locations: 🇳🇴
St Olavs Hospital, Trondheim, Norway
🇳🇴
University of North Norway, Tromsø, Norway
🇳🇴
Akershus University Hospital, Lørenskog, Norway

and more 1 locations

The Effects of Sacubitril/Valsartan Compared to Valsartan on LV Remodelling in Asymptomatic LV Systolic Dysfunction After MI

Phase 3

Completed

Conditions: Heart Failure

Interventions: Drug: sacubitril/valsartan
Drug: Valsartan

First Posted Date: 2018-06-12

Last Posted Date: 2023-05-03

Lead Sponsor: NHS Greater Glasgow and Clyde

Target Recruit Count: 93

Registration Number: NCT03552575

Locations: 🇬🇧
Glasgow Cardiovascular Research Centre, Glasgow, Scotland, United Kingdom
🇬🇧
Glasgow Clinical Research Facility, Glasgow, Scotland, United Kingdom

Patient Reported Outcomes inVestigation Following Initiation of Drug Therapy With Entresto (Sacubitril/Valsartan) in Heart Failure

Completed

Conditions: Heart Failure, Systolic

Interventions: Drug: Sacubitril/Valsartan

First Posted Date: 2017-12-29

Last Posted Date: 2019-12-13

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 402

Registration Number: NCT03387163

Locations: 🇺🇸
Novartis Investigative Site, New York, New York, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy